Company profile
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It
- CEO
- Dr. Clay B. Siegall Ph.D.
- Headquarters
- Bothell, WA, United States
- Employees
- 247
- IPO date
- Oct 2, 2020
- Sector
- Healthcare
- Industry
- Biotechnology